BofA analyst Tazeen Ahmad raised the firm’s price target on Incyte (INCY) to $87 from $86 and keeps a Buy rating on the shares. The firm ...

Shares of Incyte Corp. rallied 4.13% to $59.22 Monday, on what proved to be an all-around favorable trading session for the ...

Shares of Incyte Corp. INCY slipped 1.25% to $57.73 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte (INCY – Research Report) today and set a price target of ...

Valued at a market cap of $11.5 billion, Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, and commercializes novel medicines to address serious unmet medical ...

Valued at a market cap of $11.5 billion, Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, ...

Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes ...

Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumbersome ...